Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

05-08-2022 | JAK inhibitors | Video

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

06-07-2022 | JAK inhibitors | Ask the expert | Video

How to talk to patients about JAK inhibitor safety

10-11-2021 | ACR 2021 | Conference coverage | News

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

11-11-2020 | ACR 2020 | Conference coverage | News

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence
Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy
Image Credits